A Study of Treatment Preference During Cheek Contouring Comparing Restylane® SubQ With and Without the Addition of Lidocaine Hydrochloride

Galderma

Status

Completed

Conditions

Facial Tissue Augmentation

Treatments

Device: Restylane SubQ Lidocaine

Device: Restylane SubQ

Study type

Interventional

Funder types

Industry

Identifiers

NCT01431755

31GE1101

Details and patient eligibility

About

The objectives of this study are to evaluate the pain-relieving effect and safety of adding lidocaine hydrochloride to Restylane SubQ and to evaluate the esthetic improvement obtained. The study products will be administered in the cheek.

Full description

The Restylane SubQ gel is intended to be used for facial tissue augmentation. The lidocaine content is designed to reduce the subject's pain during treatment. The objectives of this split-face designed study are to evaluate the pain-relieving effect and safety of adding lidocaine hydrochloride to Restylane SubQ and to evaluate the esthetic improvement obtained with the dermal filler using the global esthetic improvement scale (GEIS).

Enrollment

54 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

18 years of age or older.
Intent to undergo contouring of both cheeks with 1.5 to 2 ml Restylane SubQ per cheek.
Sufficient symmetry of the face in order to ensure similar volume to be injected, similar injection technique and time for injection.
Signed informed consent.

Exclusion criteria

Surgery in the midface including aesthetic facial surgical therapy, sinus surgery or dental root surgery within the past 12 months.
Chronic infection in head and neck region.
Ongoing infections in mouth.
Tendency for edema, puffiness or swelling over the zygomatic prominence.
Active skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster near or on the area to be treated.
Previous hypersensitivity to hyaluronic acid or local anesthetics.
Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation within 10 days prior to treatment, or a history of bleeding disorders.
Cancerous or pre-cancerous lesions in the area to be treated.
Previous tissue augmenting therapy in the area to be treated with non-permanent filler, laser treatment, or chemical peeling during the last 6 months.
Permanent implant placed in the area to be treated.
Reduced sensibility in the facial region e.g. due to trauma, facial pareses, previous tissue augmenting therapy, aesthetic facial surgical therapy, laser treatment, or peeling.
Pregnancy or breast feeding.
Participation in any other clinical study within 30 days prior to inclusion.
Other condition preventing the subject to entering the study in the Investigator's opinion e.g. subjects not likely to avoid other facial cosmetic treatments below the level of the upper orbital rim, subjects anticipated to be unreliable or incapable of understanding the VAS assessment, insufficient tissue support or cover of the treatment area.